Evidence map›Paper›PMID 36205855›Full record

ArticleMolecular biology reports2022

Cardiomyocyte-specific overexpression of syndecan-4 in mice results in activation of calcineurin-NFAT signalling and exacerbated cardiac hypertrophy.

Ida G Lunde, J Magnus Aronsen, A Olav Melleby, Mari E Strand, Jonas Skogestad, Bård A Bendiksen, M Shakil Ahmed, Ivar Sjaastad, Håvard Attramadal, Cathrine R Carlson and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Unlocking the therapeutic potential of the NFAT pathway in kidney diseases.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Ida G LundeInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway. i.g.lunde@medisin.uio.no.ORCID http://orcid.org/0000-0001-9502-6841
J Magnus AronsenInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
A Olav MellebyInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Mari E StrandInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Jonas SkogestadInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Bård A BendiksenInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
M Shakil AhmedInstitute for Surgical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Ivar SjaastadInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Håvard AttramadalInstitute for Surgical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Cathrine R CarlsonInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Geir ChristensenInstitute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Oslo University Hospital · NO

Funding

Norges Forskningsråd 262013
6 · The paper itself

Abstract

backgroundCardiomyocyte hypertrophy is a hallmark of cardiac dysfunction in patients with aortic stenosis (AS), and can be triggered by left ventricular (LV) pressure overload in mice by aortic banding (AB). Syndecan-4 is a transmembrane heparan sulphate proteoglycan which is found increased in the myocardium of AS patients and AB mice. The role of syndecan-4 in cardiomyocyte hypertrophy is not well understood. PURPOSE OF THE STUDY: We developed mice with cardiomyocyte-specific overexpression of syndecan-4 (Sdc4-Tg) and subjected these to AB to examine the role of syndecan-4 in hypertrophy and activation of the pro-hypertrophic calcineurin-NFAT signalling pathway. METHODS AND

resultsSdc4-Tg mice showed exacerbated cardiac remodelling upon AB compared to wild type (WT). At 2-6 weeks post-AB, Sdc4-Tg and WT mice showed similar hypertrophic growth, while at 20 weeks post-AB, exacerbated hypertrophy and dysfunction were evident in Sdc4-Tg mice. After cross-breeding of Sdc4-Tg mice with NFAT-luciferase reporter mice, we found increased NFAT activation in Sdc4-Tg hearts after AB. Immunoprecipitation showed that calcineurin bound to syndecan-4 in Sdc4-Tg hearts. Isolated cardiomyocytes from Sdc4-Tg mice showed alterations in Ca

conclusionOur study of mice with cardiomyocyte-specific overexpression of Sdc4 have revealed that syndecan-4 is important for activation of the Ca

Indexed as

CalcineurinMyocytes, CardiacSyndecan-4AnimalsCardiomegalyCells, CulturedMiceNFATC Transcription FactorsRatsSignal TransductionCalcineurinNFATC Transcription FactorsSdc4 protein, mouseSyndecan-4CalciumFibrosisHeart failureInflammationMatrixProteoglycan

Identifiers

PMID36205855
PMCPMC9712407
OpenAlexW4303444614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.